Education to Heal Ukrainian Children's Invisible War Scars
GPE is helping increase the capacity of Ukraine's educators to reinforce children's psychosocial resilience.
More than 60,000 education professionals, including teachers, principals and school psychologists, are trained in psychosocial support and school safety.
WASHINGTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Since 2022, the war in Ukraine has eroded the mental health and well-being of the population, including approximately 5 million school-age children.
' There is no single child that is not affected by the war….61% of parents have reported to us that they have major concerns about their children's mental health and well-being because they are going through trauma. Even one single air alert during the day is enough to trigger anxiety and issues. ' - Munir Mammadzade, UNICEF Representative to Ukraine
Displacement, violence and disruption of essential services has led to acute and chronic stress, anxiety, sadness, hopelessness, sleep problems, fatigue, irritability or anger among children.
' If children's mental health issues are not addressed, they cannot learn and develop to their full potential.'
Danijel Cuturic, Education Programs Coordinator, UNESCO Ukraine
Ensuring that children have access to education during crisis provides a sense of normalcy and social support through communication with peers and educators. However, according to the Ukrainian government, around 2,000 schools remain damaged or destroyed since the Russian invasion.
Approximately 1.2 million students are accessing education online or through a blended format of online and in-person learning, relying on technology to stay connected with peers and educators.
'During the whole occupation, I have dreamed of studying because I was tired of just sitting at home and doing nothing. I did a little bit of research on the Internet, saw the subjects, tried to understand them by myself, but self-study was quite difficult. The most difficult thing was to keep your spirits up, because it was psychologically pressuring, very pressuring.' - Ivan Vasiliev, grade 11 student, Snihurivka Lyceum, Mykolaiv region
Recognizing the critical need to support children through this difficult time, Ukraine has prioritized mental health within the education sector. As part of the National Program for Mental Health and Psychosocial Support led by Olena Zelenska, Ukraine's First Lady, the Ministry of Education and Science of Ukraine is working with partners to develop policies, protocols and tools to provide students with the mental support they need.
One intervention includes training teams made up of school principals, teachers, school psychologists, security professionals, parents and caregivers across eight war-affected regions on school safety, psychosocial support and socioemotional learning.
'I have children in my class whose parents are soldiers. Some are waiting for their father or mother to call, some are waiting for both parents to call. These children need a lot of attention, support and help from teachers. We are an authority in the eyes of children, and we must be able to provide psychological help to them.' - Alyona Kolisnyk, primary school teacher, Balta Lyceum No. 2, Odesa region
'Before the war, we thought that we needed at least one professional in each school, like a psychologist. Right now, I think that all the teachers in Ukraine should have some level of experience in mental health support for their children because there are so many of them who need support from their teachers.' - Dmytro Zavgorodnii, Ukraine's Deputy Minister of Education and Science
The training is one of several interventions that was made possible thanks to a GPE Multiplier grant of US$25.5 million, which matched a total of over $25 million in cash and in-kind from Microsoft, Google and UNESCO, totaling more than $51 million in education assistance for Ukraine. The funding helps the Ministry of Education and Science provide distance learning, psychosocial support, catch-up education and other activities that are being implemented by UNESCO and UNICEF for children in conflict-affected areas.
A new GPE grant of $2.7 million, managed by the World Bank, aims to strengthen the Ministry of Education and Science's capacity to address the impact of war on students and their learning, support sector planning and implement reforms.
About GPE
GPE is the largest global fund solely dedicated to transforming education in lower-income countries, and a unique, multi-stakeholder partnership. We work to deliver quality education so that every girl and boy can have hope, opportunity and agency.
For two decades, GPE has been delivering funds and supporting solutions to build strong and resilient education systems in countries characterized by extreme poverty or conflict so that more children, especially girls, get the education they need to thrive and contribute to building a more prosperous and sustainable world.
GPE brings together all partners invested in education --lower-income countries, donors, international organizations, civil society, including youth and teacher organizations, the private sector and private foundations-- to transform education systems focusing particularly on the places and people with the greatest needs.
Our unique model has helped partner countries make significant progress in improving access, learning and equity, and achieve better outcomes for hundreds of millions of boys and girls.
P: +1 202 948 53 95
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
AI-Enabled Drug Discovery and Clinical Trials Research Report 2025-2035 Featuring AiCure, Aitia, Atomwise, BenevolentAI, Insilico Medicine, PathAI, Recursion, Saama, Schroedinger, Tempus, Unlearn.ai
Discover the thriving AI-Enabled Drug Discovery and Clinical Trials Market set to exceed USD 3 billion by 2025, with projections extending to 2035. Key growth drivers include accelerated drug development timelines and cost efficiency through AI innovations such as generative models and predictive analytics. Despite challenges like regulatory compliance and data integration, the report highlights lucrative investment areas and regional market forecasts. Gain insights into market dynamics, competitive landscapes, and strategic opportunities to stay ahead in this evolving industry. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "AI-Enabled Drug Discovery and Clinical Trials Market Report 2025-2035" report has been added to world revenue for the AI-Enabled Drug Discovery and Clinical Trials Market will surpass US$3.00 billion in 2025 with strong revenue growth projected through to 2035. The report identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new Drug Development Timelines and Cost Efficiency Driving Market GrowthKey drivers propelling the AI-enabled drug discovery and clinical trials market include the ability to reduce drug development timelines, lower research costs, and improve operational efficiency. AI technology streamlines various phases of drug discovery, including target identification, molecule screening, and clinical trial optimization, leading to faster and more cost-effective drug development. Additionally, advancements in AI-driven platforms-such as generative models for molecular design and predictive analytics for patient recruitment-are expected to further boost market growth. However, some large pharmaceutical companies remain hesitant to fully adopt AI-driven outsourcing due to concerns about data privacy, intellectual property loss, and reduced strategic control. Despite these concerns, the increasing complexity of drug development, combined with the rising costs of in-house operations, is pushing many companies to collaborate with AI solution providers to enhance efficiency and innovation. Emerging economies are also playing a critical role, as pharmaceutical firms seek to capitalize on lower operational costs and advanced AI technologies in these and Data Integration Challenges to Hamper Market GrowthWhile the adoption of AI offers significant benefits, challenges around regulatory compliance, data integration, and standardization may slow market growth. Strict regulations governing drug approval and patient data protection require AI systems to maintain transparency and explainability, adding layers of complexity to implementation. Additionally, the need for harmonized data across diverse systems and geographies poses a logistical challenge for AI-enabled real-time collaboration between AI platforms and clinical trial sites also requires robust data infrastructure and seamless integration. For instance, personalized medicine and rare disease trials require advanced AI models capable of managing vast datasets while adhering to stringent regulatory frameworks. As AI adoption grows, industry stakeholders must navigate these administrative and technical challenges to fully realize the potential of AI in drug discovery and clinical Questions Answered How is the AI-enabled drug discovery and clinical trials market evolving? What is driving and restraining the AI-enabled drug discovery and clinical trials market? How will each AI-enabled drug discovery and clinical trials submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035? How will the market shares for each AI-enabled drug discovery and clinical trials submarket develop from 2025 to 2035? What will be the main driver for the overall market from 2025 to 2035? Will leading AI-enabled drug discovery and clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others? How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035? Who are the leading players and what are their prospects over the forecast period? What are the AI-enabled drug discovery and clinical trials projects for these leading companies? How will the industry evolve during the period between 2025 and 2035? What are the implications of AI-enabled drug discovery and clinical trials projects taking place now and over the next 10 years? Is there a greater need for product commercialisation to further scale the AI-enabled drug discovery and clinical trials market? Where is the AI-enabled drug discovery and clinical trials market heading and how can you ensure you are at the forefront of the market? What are the best investment options for new product and service lines? What are the key prospects for moving companies into a new growth path and C-suite? Recent Developments On 24th March 2025, researchers at the Oxford Drug Discovery Institute have employed AI-powered databases to accelerate Alzheimer's drug discovery. By efficiently analyzing extensive biomedical data, they identified 54 immune system-related genes for potential testing, significantly reducing the time required for gene evaluation and expediting the identification of promising drug targets. On 21st March 2025, AstraZeneca announced a $2.5 billion investment over five years to establish a research and manufacturing center in Beijing, featuring an AI and data science laboratory. This initiative underscores the company's commitment to leveraging AI for enhancing early-stage research and clinical development, aiming to expedite drug discovery and reduce associated costs. On 8th January 2025, Advanced Micro Devices Inc. (AMD) invested $20 million in Absci Corp to enhance AI-backed drug discovery efforts. This collaboration aims to expedite biologics innovation and reduce costs by leveraging AMD's advanced computing capabilities, highlighting the growing role of AI in transforming traditional drug development processes. Leading Companies Profiled AiCure Aitia Atomwise Inc. BenevolentAI Insilico Medicine PathAI, Inc. Recursion Saama Technologies Schroedinger, Inc. Tempus Inc. Key Topics Covered: 1 Report Overview1.1 Objectives of the Study1.2 Introduction to AI-Enabled Drug Discovery and Clinical Trials Market1.3 What This Report Delivers1.4 Why You Should Read This Report1.5 Key Questions Answered by This Analytical Report1.6 Who is This Report for?1.7 Methodology1.8 Frequently Asked Questions (FAQs)1.9 Associated Reports1.10 About the Publisher2 Executive Summary3 Market Overview3.1 Key Findings3.2 Market Dynamics3.3 Impact Analysis3.3.1 Market Driving Factors3.3.1.1 Growing Focus on Personalized Medicine3.3.1.2 Advancements in Technology3.3.1.3 Growing Adoption of AI in Healthcare3.3.2 Market Restraining Factors3.3.2.1 Limited Data Availability and Quality3.3.2.2 Integration with Existing Infrastructure3.3.2.3 Concerns over Data Privacy and Security3.3.3 Market Opportunities3.3.3.1 Improved Patient Outcomes3.3.3.2 Increasing AI adoption in Pharma and Biopharma Clinical Trials3.3.3.3 Growing Collaborations and Partnerships3.4 Regulatory Framework3.5 Emerging Markets and Megatrends3.6 Porter's Five Forces Analysis3.7 PEST Analysis4 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Component4.1 Key Findings4.2 Component Segment: Market Attractiveness Index4.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Component4.4 Services4.4.1 Market Size by Region, 2025-2035 (US$ Million)4.4.2 Market Share by Region, 2025 & 2035 (%)4.5 Software Solutions5 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Application5.1 Key Findings5.2 Application Segment: Market Attractiveness Index5.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Application5.4 Clinical Trials5.4.1 Market Size by Region, 2025-2035 (US$ Million)5.4.2 Market Share by Region, 2025 & 2035 (%)5.5 Drug Design5.6 Data Aggregation and Analysis5.7 Drug Characterization5.8 Biomarker Research5.9 Others6 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Therapeutic Area6.1 Key Findings6.2 Therapeutic Area Segment: Market Attractiveness Index6.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Therapeutic Area6.4 Oncology6.4.1 Market Size by Region, 2025-2035 (US$ Million)6.4.2 Market Share by Region, 2025 & 2035 (%)6.5 Cardiovascular Diseases6.6 Infectious Diseases6.7 Neurodegenerative Diseases6.8 Metabolic Diseases6.9 Immunological Disorders6.10 Others7 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by End-users7.1 Key Findings7.2 End-users Segment: Market Attractiveness Index7.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by End-users7.4 Pharmaceutical & Biopharmaceutical Companies7.4.1 Market Size by Region, 2025-2035 (US$ Million)7.4.2 Market Share by Region, 2025 & 2035 (%)7.5 Contract Research Organizations (CROs)7.6 Academic Institutes and Research Centre8 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Region8.1 Key Findings8.2 Regional Market Size Estimation and Forecast For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Upturn
20 hours ago
- Business Upturn
Where the Sea Meets the Skin: Shapellx Unveils Innovative New OceanHug™ Collection Made from Oyster Shells
By GlobeNewswire Published on June 8, 2025, 18:00 IST ORLANDO, Fla., June 08, 2025 (GLOBE NEWSWIRE) — Shapellx , a leading women's shapewear brand, proudly announces the launch of OceanHug™ – a seamless women's wear collection of intimates, outerwear, and shapewear pieces crafted with a first-of-its-kind fabric made from recycled oyster shells. The new sustainable, ocean-inspired collection enhances body contours while delivering the perfect balance of style, comfort, and sustainability. Every year, millions of pounds of oyster shells are discarded, eventually ending up in landfills. Shapellx believes that beauty should never come at the expense of the environment. Every OceanHug™ piece gives new purpose to 33 recycled oyster shells, integrating them into ethically produced, performance-driven fabrics. By turning marine waste into innovation, the collection represents a fresh take on circular fashion by finding a second life for shells that promotes innovation while reducing use of virgin materials. 'As sustainability becomes a top priority for both brands and consumers, Shapellx is proud to lead with innovative materials like oyster protein that combine environmental responsibility with performance-enhancing benefits,' said Shane Shi, Vice President of Shapellx. 'We're committed to delivering more sustainable alternatives without compromising on quality or comfort. OceanHug™ is just the beginning.' The lightweight yet form-fitting OceanHug™ yarn is engineered with breathable, moisture-wicking properties, feeling silky, cool, and comfortable to the touch. The fabric uniquely incorporates collagen peptides and oyster protein fiber, rich in amino acids and trace elements, which can help to nourish the skin and strengthen its barrier. OceanHug™ also offers antibacterial properties, reducing harmful bacteria growth by 2.56%, and is specially processed to be free from irritating chemicals, making it an excellent choice for those with sensitive skin. The new lineup, built with shapewear materials to hug and comfortably embrace the body, comes in soft hues of baby blue, lavender pink, oyster white, and more. The collection includes the following products: OceanHug™ Oyster Reborn Smoothing Bodysuit The delicate lace cup edges expand the coverage around the bust, enhancing the natural bust shape and curve. The waist and abdomen shaping works to tighten and smooth targeted areas for a comfortable, sculpted silhouette. Retails for $54 and is available in sizes S-XXL and colors black, brown, baby blue, oyster white, lavender pink and bright red. OceanHug™ Oyster Reborn T-Shirt Bra The OceanHug ™ Seamless Bra is made with high-elasticity yarn and butter-soft fabric for an ultimate comfort experience. The fixed one-piece cup design reduces the risk of cup-shifting for a supportive fit. The back closure is 7cm wide, compared to the traditional 3.5cm, providing better wraparound coverage and enhanced smoothing. Retails for $49 and is available in sizes S-3XL and colors black, brown, baby blue, oyster white, beige and lavender pink. OceanHug™ Oyster Reborn Smoothing Brief The briefs feature a mid-waist, hip-hugging seamless design for stable coverage, preventing unwanted digging and squeezing while delivering stretch to fit perfectly on all body types. Made from skin-friendly, soft modal fabric, it provides a gentle and refreshing touch on the skin. Retails for $9 and is available in sizes S-3XL and colors black, brown, baby blue, oyster white, beige and lavender pink. OceanHug™ Oyster Reborn Smoothing Cami The V-neckline highlights the collarbone, creating a feminine, flattering look. The built-in 3D molded cups comfortably lift and shape the bust for all-day support. It features an anti-slip grip at the bottom hem to prevent rolling and ensure a smooth, stable fit. The compression fabric around the waist and abdomen smooths the area and provides comfortable shaping. Retails for $49 and is available in sizes S-XXL and colors black, brown, baby blue, oyster white, beige and lavender pink. To celebrate both the OceanHug™ launch and World Ocean Day on June 8, Shapellx hosted a pop-up event in NoHo, New York. Attendees were able to experience the OceanHug™ fabric firsthand and received a special gift. Designed to suit your everyday life and standout moments, Shapellx's new OceanHug™ collection is available to purchase at . To learn more about the collection and keep up with the brand, follow along on Instagram and TikTok . About Shapellx Shapellx is a full-category shapewear brand built on cutting-edge shaping technology and refined design aesthetics. Through premium international retailers such as Nordstrom and its own online platform, Shapellx connects with women who value both quality and style. The brand is dedicated to meeting the dual needs of fashion expression and body contouring in everyday wear, empowering women to radiate confidence from the inside out. Contact:Melina Schaefer [email protected] A video accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.


Business Upturn
2 days ago
- Business Upturn
Total Control 24: Inside Look at the TC24 Brazilian Jelly Formula for Men
Tallmadge, June 07, 2025 (GLOBE NEWSWIRE) — Total Control 24, a performance-focused supplement brand from Adem Naturals, has updated its official website to highlight its natural daily supplement designed to support sustained energy, focus, and productivity in adults. Now available across the United States, the once-daily capsule is intended for individuals seeking an easy-to-use, natural solution to help power through long workdays or physically demanding routines. According to the official website ( Total Control 24 is formulated to work in harmony with the body's internal systems to promote mental clarity, energy maintenance, and a more productive daily rhythm. The supplement is designed to support active lifestyles without requiring restrictive diets, stimulants, or complicated regimens. 'We created Total Control 24 to give people a clean, natural edge for staying energized and sharp throughout the day,' said a spokesperson for Adem Naturals. 'This product reflects our commitment to simplicity, transparency, and functional wellness.' The company affirms that Total Control 24 is manufactured in facilities that follow strict quality and safety protocols. The formulation is composed of carefully selected ingredients chosen to align with common adult wellness goals such as daytime focus, endurance, and healthy performance. As stated on the product website, Total Control 24 includes a satisfaction guarantee for new customers. Those interested in learning more about the product's intended uses or accessing exclusive promotions can find full details, customer support, and purchasing options online. About Total Control 24 Total Control 24 by Adem Naturals is a U.S.-based wellness brand focused on delivering natural, easy-to-use supplements that support everyday energy, focus, and stamina. The company emphasizes clean formulas, customer satisfaction, and practical wellness tools to help adults feel their best. Product and Contact Information Brand: Total Control 24 Website: Email: [email protected] Phone: 1 (814) 885-4823 (Monday through Friday) Mailing Address: Adem Naturals285 Northeast Ave Tallmadge, OH 44278